Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$55.62 +3.8%	$43.96	$21.02 ▼ $58.40	$4.43B	-0.16	1.01 million shs	2.22 million shs
GPCR Structure Therapeutics	$21.68 -2.4%	$22.64	$13.22 ▼ $49.91	$1.24B	-1.87	853,335 shs	669,777 shs
RYTM Rhythm Pharmaceuticals	$62.90 -0.2%	$62.07	$39.46 ▼ $69.89	$4.00B	2.3	556,906 shs	541,189 shs
ZLAB Zai Lab	$41.00 -4.7%	$31.78	$16.01 ▼ $44.34	$4.52B	0.96	897,658 shs	1.02 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	0.00%	+2.47%	+39.19%	+25.98%	+128.98%
GPCR Structure Therapeutics	0.00%	+2.60%	-11.26%	+2.99%	-58.31%
RYTM Rhythm Pharmaceuticals	0.00%	-7.65%	+4.52%	+23.41%	+48.81%
ZLAB Zai Lab	0.00%	+7.58%	+42.61%	+7.33%	+105.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.6067 of 5 stars	3.5	1.0	4.7	1.9	1.7	0.0
GPCR Structure Therapeutics	2.427 of 5 stars	3.5	2.0	0.0	2.8	1.7	0.6
RYTM Rhythm Pharmaceuticals	4.1433 of 5 stars	3.5	3.0	4.3	3.1	0.8	0.6
ZLAB Zai Lab	1.2697 of 5 stars	2.4	1.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	48.33% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.50	252.86% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$76.62	21.81% Upside
ZLAB Zai Lab	2.75	Moderate Buy	$47.37	15.53% Upside

Current Analyst Ratings Breakdown

Latest GPCR, AKRO, RYTM, and ZLAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/8/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/8/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$81.00 ➝ $92.00
4/8/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $80.00
4/7/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$80.00 ➝ $91.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$9.61 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A
RYTM Rhythm Pharmaceuticals	$136.86M	29.24	N/A	N/A	$2.87 per share	21.92
ZLAB Zai Lab	$418.33M	10.81	N/A	N/A	$8.05 per share	5.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$151.76M	-$1.95	N/A	N/A	N/A	N/A	-32.46%	-29.83%	8/8/2025 (Estimated)
GPCR Structure Therapeutics	-$89.62M	-$0.87	N/A	N/A	N/A	N/A	-16.37%	-15.68%	8/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$184.68M	-$2.81	N/A	N/A	N/A	-230.07%	-367.36%	-77.47%	8/5/2025 (Estimated)
ZLAB Zai Lab	-$334.62M	-$2.49	N/A	N/A	N/A	-76.14%	-36.97%	-27.10%	8/5/2025 (Estimated)

Latest GPCR, AKRO, RYTM, and ZLAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.05	17.25	17.25
GPCR Structure Therapeutics	N/A	27.63	27.63
RYTM Rhythm Pharmaceuticals	N/A	3.49	3.34
ZLAB Zai Lab	N/A	3.01	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
GPCR Structure Therapeutics	91.78%
RYTM Rhythm Pharmaceuticals	N/A
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
GPCR Structure Therapeutics	9.43%
RYTM Rhythm Pharmaceuticals	6.10%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	64.26 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	58.02 million	Optionable
ZLAB Zai Lab	1,950	110.33 million	94.24 million	Optionable

GPCR, AKRO, RYTM, and ZLAB Headlines

Recent News About These Companies

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

June 13 at 9:31 AM | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?

June 12 at 12:20 PM | marketbeat.com

Cantor Fitzgerald Forecasts Zai Lab FY2026 Earnings

June 11, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Sets New 1-Year High - Here's What Happened

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Trims Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

June 8, 2025 | marketbeat.com

Yajing Chen Sells 9,618 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

June 5, 2025 | marketbeat.com

Zai Lab Limited (NASDAQ:ZLAB) CFO Sells $288,540.00 in Stock

June 5, 2025 | insidertrades.com

Bank of America Corp DE Has $1.63 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

June 5, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's Why

June 4, 2025 | marketbeat.com

Squarepoint Ops LLC Acquires Shares of 27,961 Zai Lab Limited (NASDAQ:ZLAB)

June 3, 2025 | marketbeat.com

Legacy Wealth Asset Management LLC Buys Shares of 22,285 Zai Lab Limited (NASDAQ:ZLAB)

June 2, 2025 | marketbeat.com

Millennium Management LLC Sells 15,023 Shares of Zai Lab Limited (NASDAQ:ZLAB)

June 1, 2025 | marketbeat.com

Zai Lab Limited (NASDAQ:ZLAB) Sees Large Drop in Short Interest

June 1, 2025 | marketbeat.com

Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial

May 31, 2025 | insidermonkey.com

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025 | businesswire.com

Zai Lab Announces Participation in Investor Conferences in June 2025

May 30, 2025 | businesswire.com

Northern Trust Corp Increases Holdings in Zai Lab Limited (NASDAQ:ZLAB)

May 29, 2025 | marketbeat.com

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 28, 2025 | seekingalpha.com

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 28, 2025 | seekingalpha.com

BNP Paribas Financial Markets Purchases 18,472 Shares of Zai Lab Limited (NASDAQ:ZLAB)

May 26, 2025 | marketbeat.com

Twinbeech Capital LP Buys Shares of 27,039 Zai Lab Limited (NASDAQ:ZLAB)

May 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR, AKRO, RYTM, and ZLAB Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$55.62 +2.06 (+3.85%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$55.39 -0.23 (-0.41%)

As of 06/13/2025 07:12 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Structure Therapeutics NASDAQ:GPCR

$21.68 -0.54 (-2.43%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.70 +0.02 (+0.07%)

As of 06/13/2025 05:42 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$62.90 -0.12 (-0.19%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$63.76 +0.86 (+1.37%)

As of 06/13/2025 06:37 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Zai Lab NASDAQ:ZLAB

$41.00 -2.03 (-4.72%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$40.87 -0.13 (-0.31%)

As of 06/13/2025 07:55 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time